Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

365 ARTÍCULOS , VIENDO DEL 76 AL 90

Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe

Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, Schwam E, Schindler R, Hey-Hadavi J, DeMicco DA, Breazna A; LEADe Investigators.

Neurology. 2010 Mar 23;74(12):956-64. doi: 10.1212/WNL.0b013e3181d6476a. Epub 2010 Mar 3.

Novel therapeutics for Alzheimer's disease: an update

Bonda DJ, Lee HP, Lee HG, Friedlich AL, Perry G, Zhu X, Smith MA.

Curr Opin Drug Discov Devel. 2010 Mar;13(2):235-46.

Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention

Cribbs DH.

CNS Neurol Disord Drug Targets. 2010 Apr;9(2):207-16. doi: 10.2174/187152710791012080.

Amyloid-beta immunotherapy for Alzheimer's disease

Fu HJ, Liu B, Frost JL, Lemere CA.

CNS Neurol Disord Drug Targets. 2010 Apr;9(2):197-206. doi: 10.2174/187152710791012017.

Re-balancing of inflammation and abeta immunity as a therapeutic for Alzheimer's disease-view from the bedside

Fiala M.

CNS Neurol Disord Drug Targets. 2010 Apr;9(2):192-6. doi: 10.2174/187152710791012044.

Assessing activation states in microglia

Colton C, Wilcock DM.

CNS Neurol Disord Drug Targets. 2010 Apr;9(2):174-91. doi: 10.2174/187152710791012053.

Mechanisms of mononuclear phagocyte recruitment in Alzheimer's disease

Hickman SE, El Khoury J.

CNS Neurol Disord Drug Targets. 2010 Apr;9(2):168-73. doi: 10.2174/187152710791011982.

Microglia and inflammation in Alzheimer's disease

Mandrekar-Colucci S, Landreth GE.

CNS Neurol Disord Drug Targets. 2010 Apr;9(2):156-67. doi: 10.2174/187152710791012071.

Mechanisms of action of non-steroidal anti-inflammatory drugs for the prevention of Alzheimer's disease

Cole GM, Frautschy SA.

CNS Neurol Disord Drug Targets. 2010 Apr;9(2):140-8. doi: 10.2174/187152710791011991.

Inflammation, immunity, and Alzheimer's disease

Town T.

CNS Neurol Disord Drug Targets. 2010 Apr;9(2):129-31. doi: 10.2174/187152710791012008.

The pulse of drug development for Alzheimer's disease

Rafii MS.

Rev Recent Clin Trials. 2010 Jan;5(1):57-62. doi: 10.2174/157488710790820490.

Exploring new indications for statins beyond atherosclerosis: Successes and setbacks

Waters DD.

J Cardiol. 2010 Mar;55(2):155-62. doi: 10.1016/j.jjcc.2009.12.003. Epub 2010 Jan 7.

Docosahexaenoic acid and synaptic protection in Alzheimer's disease mice

Oster T, Pillot T.

Biochim Biophys Acta. 2010 Aug;1801(8):791-8. doi: 10.1016/j.bbalip.2010.02.011. Epub 2010 Mar 6.

Cholesterol in Alzheimer's disease and other amyloidogenic disorders

Harris JR, Milton NG.

Subcell Biochem. 2010;51:47-75. doi: 10.1007/978-90-481-8622-8_2.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias